Evidence map›Paper›PMID 29058358›Full record

Trial reportHuman brain mapping2018

An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers.

Peter C T Hawkins, Tobias C Wood, Anthony C Vernon, Alessandro Bertolino, Fabio Sambataro, Juergen Dukart, Emilio Merlo-Pich, Celine Risterucci, Hanna Silber-Baumann, Eamonn Walsh and 3 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Human brain mapping, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Antipsychotics cause reversible structural brain changes within one week.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  4. Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Peter C T HawkinsCentre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-2256-1648
Tobias C WoodCentre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Anthony C VernonDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Alessandro BertolinoDepartment of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari BA, Italy.
Fabio SambataroDepartment of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy.
Juergen DukartTranslational Medicine Neuroscience and Biomarkers, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Emilio Merlo-PichCNS Therapeutic Area Unit, Takeda Development Centre Europe, London, United Kingdom.
Celine RisterucciPharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Hanna Silber-BaumannPharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Eamonn WalshInstitute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
Ndabezinhle MazibukoCentre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Fernando O ZelayaCentre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Mitul A MehtaCentre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Wellcome Centre for Human Neuroimaging · GBRoche (Switzerland) · CHKing's College London · GBTakeda (United Kingdom) · GBUniversity of Bari Aldo Moro · ITUniversity of Udine · IT

Funding

Medical Research Council MR/N025377/1Medical Research Council MR/N026063/1
6 · The paper itself

Abstract

Chronic administration of antipsychotic drugs has been linked to structural brain changes observed in patients with schizophrenia. Recent MRI studies have shown rapid changes in regional brain volume following just a single dose of these drugs. However, it is not clear if these changes represent real volume changes or are artefacts ("apparent" volume changes) due to drug-induced physiological changes, such as increased cerebral blood flow (CBF). To address this, we examined the effects of a single, clinical dose of three commonly prescribed antipsychotics on quantitative measures of T1 and regional blood flow of the healthy human brain. Males (n = 42) were randomly assigned to one of two parallel groups in a double-blind, placebo-controlled, randomized, three-period cross-over study design. One group received a single oral dose of either 0.5 or 2 mg of risperidone or placebo during each visit. The other received olanzapine (7.5 mg), haloperidol (3 mg), or placebo. MR measures of quantitative T1, CBF, and T1-weighted images were acquired at the estimated peak plasma concentration of the drug. All three drugs caused localized increases in striatal blood flow, although drug and region specific effects were also apparent. In contrast, all assessments of T1 and brain volume remained stable across sessions, even in those areas experiencing large changes in CBF. This illustrates that a single clinically relevant oral dose of an antipsychotic has no detectable acute effect on T1 in healthy volunteers. We further provide a methodology for applying quantitative imaging methods to assess the acute effects of other compounds on structural MRI metrics. Hum Brain Mapp 39:319-331, 2018. © 2017 Wiley Periodicals, Inc.

Indexed as

AdultAntipsychotic AgentsBenzodiazepinesBrainBrain MappingCerebrovascular CirculationCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodHaloperidolHumansMagnetic Resonance ImagingMaleOlanzapineRisperidoneYoung AdultAntipsychotic AgentsBenzodiazepinesHaloperidolOlanzapineRisperidoneacuteantipsychoticsCBFrelaxometrystructural MRIT1

Identifiers

PMID29058358
PMCPMC6866296
OpenAlexW2765648396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.